{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:24:50Z","timestamp":1788870290893,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","award":["HT\/br\/06 037"],"award-info":[{"award-number":["HT\/br\/06 037"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Dutch National Institute for Public Health and the Environment","award":["3022\/07 DG MS\/CvB\/NvN"],"award-info":[{"award-number":["3022\/07 DG MS\/CvB\/NvN"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.ejca.2010.09.030","type":"journal-article","created":{"date-parts":[[2010,10,23]],"date-time":"2010-10-23T04:28:34Z","timestamp":1287808114000},"page":"428-435","source":"Crossref","is-referenced-by-count":24,"title":["Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?"],"prefix":"10.1016","volume":"47","author":[{"given":"Inge M.C.M.","family":"de Kok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Dik F.","family":"Habbema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"van Rosmalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"van Ballegooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.09.030_b0005","unstructured":"Netherlands Cancer Registry. Incidence and mortality figures cervical cancer, <www.ikcnet.nl>; 2007."},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2010.09.030_b0010","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"Chapter 2: the burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.ejca.2010.09.030_b0015","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.vaccine.2006.05.116","article-title":"Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes","volume":"24","author":"Garnett","year":"2006","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.ejca.2010.09.030_b0020","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ejca.2010.09.030_b0025","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs","volume":"290","author":"Kulasingam","year":"2003","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.ejca.2010.09.030_b0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost-effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.ejca.2010.09.030_b0035","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"9574","key":"10.1016\/j.ejca.2010.09.030_b0040","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2010.09.030_b0045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3201\/eid1402.070499","article-title":"Cost-effectiveness of human papillomavirus vaccination in the United States","volume":"14","author":"Chesson","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.ejca.2010.09.030_b0050","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl. 10","key":"10.1016\/j.ejca.2010.09.030_b0055","doi-asserted-by":"crossref","first-page":"K76","DOI":"10.1016\/j.vaccine.2008.06.009","article-title":"Modeling cervical cancer prevention in developed countries","volume":"26","author":"Kim","year":"2008","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.ejca.2010.09.030_b0060","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.ejca.2009.07.020","article-title":"Cervical cancer screening policies and coverage in Europe","volume":"45","author":"Anttila","year":"2009","journal-title":"Eur J Cancer"},{"issue":"15","key":"10.1016\/j.ejca.2010.09.030_b0065","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.ejca.2009.07.018","article-title":"Trends of cervical cancer mortality in the member states of the European Union","volume":"45","author":"Arbyn","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.09.030_b0070","unstructured":"Netherlands Cancer Registry (NCR), <www.ikcnet.nl>; 1999\u20132003."},{"key":"10.1016\/j.ejca.2010.09.030_b0075","unstructured":"Statistics Netherlands, <www.CBS.nl>; 2003."},{"issue":"32","key":"10.1016\/j.ejca.2010.09.030_b0080","first-page":"21","article-title":"Trends in incidence and mortality of head and neck cancer in the Netherlands (1989\u20132000)","volume":"16","author":"Kos","year":"2004","journal-title":"Hoofd-Hals J"},{"issue":"3","key":"10.1016\/j.ejca.2010.09.030_b0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10729-006-9096-y","article-title":"Cost assessment and price setting of inpatient care in The Netherlands. The DBC case-mix system","volume":"9","author":"Oostenbrink","year":"2006","journal-title":"Health Care Manag Sci"},{"key":"10.1016\/j.ejca.2010.09.030_b0090","unstructured":"Nederlandse Zorg Autoriteit, <www.NZA.nl>; 2008."},{"issue":"7","key":"10.1016\/j.ejca.2010.09.030_b0095","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.socscimed.2006.04.018","article-title":"Health care costs in the last year of life\u2013the Dutch experience","volume":"63","author":"Polder","year":"2006","journal-title":"Soc Sci Med"},{"issue":"8","key":"10.1016\/j.ejca.2010.09.030_b0100","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/sj.bjc.6605018","article-title":"The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening","volume":"100","author":"de Kok","year":"2009","journal-title":"Br J Cancer"},{"issue":"15","key":"10.1016\/j.ejca.2010.09.030_b0105","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/jnci\/djp183","article-title":"Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands","volume":"101","author":"de Kok","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.09.030_b0110","unstructured":"Statistics Netherlands (CBS). Population by sex, age, and marital status, <www.cbs.nl>; 2009."},{"key":"10.1016\/j.ejca.2010.09.030_b0115","unstructured":"World Health Organisation (WHO). Health expenditure per capita (PPP:US$), <www.GlobalHealthFacts.org> (07\/05\/2008)."},{"key":"10.1016\/j.ejca.2010.09.030_b0120","unstructured":"WHO\/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics, <www.who.int\/hpvcentre>; 2007 (07\/05\/2008)."},{"key":"10.1016\/j.ejca.2010.09.030_b0125","unstructured":"GLOBOCAN. Cancer incidence, mortality and prevalence worldwide, <http:\/\/www-dep.iarc.fr\/>; 2002."},{"key":"10.1016\/j.ejca.2010.09.030_b0130","unstructured":"Surveillance Epidemiology and End Results (SEER). Cancer stat fact sheets, <http:\/\/seer.cancer.gov>; 2001\u20132005."},{"key":"10.1016\/j.ejca.2010.09.030_b0135","unstructured":"Gerda Engholm, Jacques Ferlay, Niels Christensen, Freddie Bray, \u00c5sa Klint, El\u00ednborg \u00d3lafsd\u00f3ttir, et al. NORDCAN: cancer incidence, mortality and prevalence in the nordic countries, version 3.2 (http:\/\/www.ancr.nu). Association of Nordic Cancer Registries, Danish Cancer Society; 2008."},{"key":"10.1016\/j.ejca.2010.09.030_b0140","unstructured":"Statistics Finland. Finland in figures, population, <http:\/\/www.stat.fi>; 2007."},{"key":"10.1016\/j.ejca.2010.09.030_b0145","unstructured":"Statistics Denmark. Population 1 January by region, age, sex, marital status, <http:\/\/www.statbank.dk>; 2006."},{"key":"10.1016\/j.ejca.2010.09.030_b0150","unstructured":"Cancer Research UK. CancerStats, <http:\/\/info.cancerresearchuk.org\/>; 2004."},{"key":"10.1016\/j.ejca.2010.09.030_b0155","unstructured":"Office for National Statistics. Key population and vital statistics, <http:\/\/www.statistics.gov.uk>; 2006."},{"key":"10.1016\/j.ejca.2010.09.030_b0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-6-4","article-title":"Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis","volume":"6","author":"Kulasingam","year":"2008","journal-title":"Cost Eff Resour Alloc"},{"issue":"19","key":"10.1016\/j.ejca.2010.09.030_b0210","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Future II Study Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"9518","key":"10.1016\/j.ejca.2010.09.030_b0170","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2010.09.030_b0175","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1006\/gyno.2001.6502","article-title":"A population-based study of squamous cell vaginal cancer: HPV and cofactors","volume":"84","author":"Daling","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2010.09.030_b0180","first-page":"753","article-title":"Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses","volume":"59","author":"Frisch","year":"1999","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2010.09.030_b0185","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0029-7844(96)00376-6","article-title":"Human papillomavirus in squamous cell carcinoma of the vulva by polymerase chain reaction","volume":"89","author":"Iwasawa","year":"1997","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ejca.2010.09.030_b0190","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.ejca.2010.09.030_b0195","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0002-9440(10)62506-0","article-title":"Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis","volume":"159","author":"Rubin","year":"2001","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2010.09.030_b0200","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.09.030_b0205","unstructured":"College voor Zorgverzekeringen. Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie. March 2006."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910009512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910009512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T03:20:01Z","timestamp":1544152801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910009512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0959804910009512"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.09.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}